INNOTEST® hTAU Ag

The INNOTEST hTAU Ag is a solid-phase enzyme immunoassay for the quantitative determination of Tau protein in human cerebrospinal fluid (CSF).

This assay measures the biomarker called total Tau, including the six isoforms (352 to 441 amino acids) from the brain.

The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-6). 

    For research use only
    INNOTEST® hTAU Ag

    Product number 81579

    96 Tests
    Please contact your local Fujirebio representative for the availability of this product in your country.

    Click here to navigate

    • Details
    • Conditions of sale
    • Citations
    • Documentation
    • Insights
    • Related products
    • Webinars

    • Details

      Features & Benefits     

      • User-friendly enzyme  immunoassay, standard technology
      • Generic and color-coded components
      • Easily automated on microplate processor (generic components)
      • Ready-to-use Calibrators reduce inter and intra run variation
      • Run Validation Controls for assay run validation
      • Small sample volume: 25 µL CSF. Duplicate testing is strongly recommended and requires 2 x 25 µL CSF.
      • Calibrator range: 50 to 2500 pg/mL
      • This assay should be used in combination with the Tau Ag CAL-RVC pack, article no. 81580.

       

      References

      1. Andreasen et al. Evaluation of CSF-tau and CSF- Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373-379.
      2. Sunderland et al. Decreased b-amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer disease. Journal of the American Medical Association 2003;289:2094-2103.
      3. Hansson et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
      4. Mattsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302(4): 385-393.
      5. Tabaraud et al. Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand. 2012; 125(6): 416-23.
      6. Buchhave et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69(1): 98-106.

      Additional useful information about Alzheimer’s disease can be found on the following websites:

      The Alzheimer forum site:

    • Conditions of sale

      To read the end user conditions of sale for this product please visit our Resource center.

    • Citations

      The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.

    • Insights

      • Review past webinars

      Neurological disorders
      Replay available
      2021/11/18 - 18 November 2021

      Preparing for the future of plasma based Alzheimers disease diagnostics

      Watch replay

    Veuillez confirmer que vous êtes un professionnel de la santé

    Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

    Choose your country or region

    Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
    The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.